Daily filing brief

10 Important BSE and NSE Announcements — 7 July 2026

By Daily BrieferPublished

Here are 10 notable company announcements from 7 July 2026. The brief brings the key developments together in one place and keeps the essential details easy to scan.

  1. Econo Trade (India) Ltd

    SEBI final order finds Hanif Shekh-led group manipulated five scrips; imposes disgorgement, penalties, and debarments

    General

    Enforcement actions and outcomes

    • Final order targets Hanif Shekh and affiliates for price manipulation across five scrips.
    • Defines PV Influencers, Collaborators, and Offloaders; funds routed to Hanif Shekh-controlled entities.
    • Disgorgement amounts per Noticee are listed in Annexure-A; penalties up to ₹10 crore for Hanif.
    • Debarment ranges from seven years for Hanif to four years for many others.
    • Interest at 12% per annum on disgorged amounts from Oct 21, 2020 until payment.
    • Disgorgement and penalties must be paid to IPEF within 45 days.
    • Noticees 2 and 127 deceased; disgorgement directed through their legal representatives.
    • Final order comes into force immediately.
    • The scheme involved 226 entities across five scrips between 2017 and 2020.
    • PV Influencers and Offloaders structured trades, leading to offloading and profits routed via conduits.
    View source

  2. Adani Enterprises Ltd

    Adani Enterprises completes QIP closure; allocates 52,029,136 equity shares to QIBs at ₹2,883 each

    Qualified Institutional Placement

    QIP overview

    • Purpose: raise funds through QIP from eligible qualified institutional buyers.
    • Security: equity shares (face value ₹1).
    • Shares allocated: 52,029,136 equity shares.
    • Issue price: ₹2,883; floor price: ₹3,034.68; discount: ₹151.68 (5%).
    • Total amount: ₹149,999,999,088.
    • Approval: QIP Committee approved closure, allocation, placement document, and allocation note.
    • Closing date: July 7, 2026.
    • Placement document dated: July 7, 2026.
    View source

  3. Restaurant Brands Asia Ltd

    Inspira Global completes acquisition of Burger King operator in India; 41.78% stake held

    Press Release / Media Release

    Transaction overview

    • Total transaction value ~INR 2235 crore, one of India's largest QSR deals.
    • Inspira Global owns 41.78% post-completion.
    • Warrants exercise could lift stake to 48.04% after INR 450 crore infusion.
    • Completion followed open offer, regulatory approvals and closing conditions.

    Governance

    • Madhusudan Agrawal appointed Chairman.
    • Aayush Agrawal appointed non-executive director.

    Franchise & operations

    • Burger King India and Indonesia master franchises extended through 2050.
    • Continues to operate Burger King and Popeyes under existing master agreements.

    Strategic outlook

    • Focus on expanding restaurant network, customer experience, and technology investments.
    View source

  4. Shree Cement Ltd

    Shree Cement Ltd – Reg. 34(1) Annual Report FY2025-26: Key financials, liquidity, and expansion plans

    Reg. 34 (1) Annual Report

    Financial performance

    • Revenue from operations ₹20,943.47 Cr; up from ₹19,282.83 Cr.
    • PAT attributable to owners ₹1,743.56 Cr.
    • EBITDA margin 24.80%.

    Dividends & capital

    • Final dividend ₹70 per share; total ₹252.57 Cr.
    • Debt-to-equity 0.07x; borrowings ₹1,580.79 Cr.

    Geography & assets

    • Revenue India ₹18,840.58 Cr; overseas ₹2,102.89 Cr.

    Corporate actions & governance

    • Amalgamation: Western India Commercial Co. merged into NBI; effective 18 Dec 2024.
    • Purchases from Global Smart Comtrade ₹679.68 Cr; ASAT Logistics ₹455.80 Cr.

    Risk & compliance

    • CCI penalties ₹397.51 Cr; differential subsidy ₹37.84 Cr; ₹317.54 not received.

    Strategy & expansion

    • Mega expansion: Meghalaya plant clinker 0.95 MTPA, cement 0.99 MTPA; UAE grinding capacity 2.5 MTPA by Sept 2026.
    View source

  5. EL CID Investments Ltd

    Elcid Investments Limited FY2025-26: Results, NBFC status, governance and outlook

    Reg. 34 (1) Annual Report

    Financial highlights

    • Standalone total income ₹9,482.70 Lakhs; down 32.6% YoY.
    • Consolidated total income ₹13,538.00 Lakhs; down 36.6% YoY.
    • Standalone PAT ₹7,622.80 Lakhs; down 24.5%.
    • Consolidated PAT ₹10,852.04 Lakhs; down 29.0%.
    • Standalone EPS ₹3,811.40; Consolidated EPS ₹5,426.02.
    • Standalone net profit margin 80.38%; Consolidated 80.16%.
    • Standalone current ratio 4.14x; Consolidated 3.97x.
    • Debt-free balance sheet; zero borrowings; strong liquidity.

    Dividends & capital returns

    • Final dividend ₹25 per equity share for FY2025-26.
    • Total dividend ₹50.00 Lakhs; record date 24 Jul 2026.
    • Dividend payable after AGM, subject to shareholder approval.
    • 45th AGM on 31 Jul 2026; VC/OAVM mode.

    Governance & board changes

    • Amrita Vakil appointed Whole-Time Director on 24 May 2025.
    • Margarette Shwetha Thomas appointed Independent Director on 24 May 2025.
    • Ragini Vakil appointed Director on 24 May 2025.
    • Essaji Vahanvati reappointed Independent Director on 2 Nov 2025.
    • Kartikeya Kaji to be reappointed Independent Director (2027–2032).
    • Board meetings: seven in FY25-26; six directors; three independents.
    • Committees: Audit, NRC, SRC, CSR.

    Subsidiaries & regulatory changes

    • Two material subsidiaries: Murahar Investments & Trading Co. Ltd; Suptaswar Investments & Trading Co. Ltd; 100% owned.
    • RBI COR Type-1 NBFC-ND for both subsidiaries; COR dated 15 Sep 2025.
    • MOA amended; CINs updated: Elcid L64990MH1981PLC025770; Murahar U64990MH1979PLC021880; Suptaswar U64990MH1979PLC021876.
    • Consolidated statements include subsidiary notes; available on company website.

    CSR policy & projects

    • CSR policy approved; CSR Committee oversees initiatives; policy on website.
    • CSR 2025-26 projects: Cancer treatment in Maharashtra; Palanpur education scholarships; Palanpur scholarships.
    • Average net profit ₹24,41,80,662; CSR obligation ₹48,83,613.
    • CSR spend ₹50,00,000; excess ₹1,16,387 carried forward.

    Audit & internal controls

    • Standalone Ind AS: Unmodified opinion from VK Beswal & Associates.
    • Internal controls deemed adequate; no material weaknesses disclosed.
    • Secretarial Audit: Annexure 4; no observations identified.
    • Consolidated: Unmodified opinion; no material misstatements noted.

    Risks & outlook

    • Positive long-term outlook driven by India's growth, digital adoption and infrastructure.
    • Risks: geopolitical tensions, inflation, NBFC regulatory changes, portfolio concentration.
    • Outlook: RBI policy easing, strong SIP/institutional flows, FPIs into government securities.
    • Portfolio to deliver earnings as the domestic cycle strengthens; maintain debt-free stance.

    AGM & investor communications

    • Annual General Meeting through VC/OAVM; deemed venue at registered office.
    • Record date for dividend: 24 Jul 2026.
    • E-voting window: 27-30 Jul 2026; remote via CDSL; details on company site.
    View source

  6. TeamLease Services Ltd

    TeamLease announces buyback of up to 14,87,500 equity shares for ₹238 crore at ₹1,600 each via tender offer

    Buy back

    Buyback details

    • Buyback size: up to 14,87,500 equity shares at ₹1,600 per share; ₹238 crore total.
    • Record date: 3-Jul-2026; Buyback opens 9-Jul-2026; closes 15-Jul-2026.
    • Small shareholders: 15% reserved, amounting to 2,23,125 shares.
    • Entitlement: Reserved 14/53; General 14/163.
    • Promoter participation: HR Offshoring Ventures to tender 1,29,234 shares; pre-Buyback holding 31.11%.
    • Post-Buyback promoter stake: 33.29%; public stake: 66.71%.
    • Designated exchange: BSE; tender via stock exchange mechanism.
    • Funding: from free reserves; no borrowings; escrow ₹38.80 crore (16.30% of offer size).
    • Escrow: HDFC Bank as Escrow Agent; escrow account opened.
    • Registrar: KFin Technologies Limited; Manager to Buyback: Nuvama Wealth Management Limited.
    • Tax: no additional tax under 115QA for buybacks; capital gains taxed to shareholders.
    • TDS: not applicable for resident shareholders; NRIs require RBI/FEMA compliance.
    • Listing/ISIN: NSE and BSE; ISIN INE985S01024.
    • Board approval: 20-May-2026; postal ballot results on 29-Jun-2026.
    View source

  7. Sun Pharmaceutical Industries Ltd

    Sun Pharma FY26: Rs 582.2bn sales, Rs 177.3bn EBITDA; Organon acquisition announced

    Investor Presentation

    Business Overview

    • Global specialty generic company with Innovative Medicines, branded generics, and APIs.
    • Geographic footprint across US, India, Emerging Markets, ROW (100+ countries).
    • Innovative Medicines contributed 22% of FY26 sales; US-focused portfolio.
    • 40 manufacturing facilities; several USFDA-approved sites; R&D spend 6.1% of sales.

    Operational Highlights

    • FY26 sales Rs 582.2 bn; EBITDA Rs 177.3 bn; net profit Rs 114.8 bn.
    • US Formulations 29% of revenue; India 33%; Emerging Markets 19%; ROW 15%.
    • Innovative Medicines marketed globally; 29 products marketed.
    • Launched Leqselvi and Unloxcyt in FY26.
    • Acquisitions: Checkpoint Therapeutics (FY25); Concert Pharma (FY23); Pola Japan (2019).
    • 40 manufacturing facilities; USFDA approvals across sites.

    Financial Performance

    • FY26 revenue 582.2 bn; EBITDA margin 30.3%; net margin 19.6%.
    • R&D spend 6.1% of sales; R&D Rs 35.54 bn in FY26.
    • Net cash (excluding debt) around Rs 40.8 bn; gross debt Rs 88.1 bn (FY26).
    • Market cap Rs 4,460 bn (~US$47 bn) as of 30 Jun 2026.

    Capital Structure & Liquidity

    • Gross debt ranged Rs 74.9 bn (FY22) to Rs 119.4 bn (FY25), Rs 88.1 bn (FY26).
    • Net cash position around Rs 40.8 bn in FY26.
    • Strong cash generation; market capitalization ~Rs 4.46 trillion.

    Strategic Priorities & Outlook

    • Target mid-to-high single-digit consolidated topline growth for FY26.
    • Increase contribution of Innovative Medicines and complex products.
    • Invest in differentiated products; bridge gaps via acquisitions with ROI focus.
    • Organon acquisition announced in 2026 to expand Women’s Health and biosimilars.

    Risks

    • Regulatory approvals and market risks; pipeline execution uncertainty.
    • Competitive dynamics in US generics and global markets.

    Governance & Leadership

    • Board of nine members; five independent; Lead Independent Director Dr. Pawan Goenka.
    • Independent directors: Gautam B. Doshi, Dr. Andreas Eugen Busch, Rolf Hoffmann, Satyavati Berera.
    • Company Secretary and Compliance Officer: Anoop Deshpande.
    View source

  8. Mercantile Ventures Ltd

    NCLT sanctions amalgamation with 10:36 share exchange; effective after filing with ROC

    Scheme of Arrangement

    Overview

    • Amalgamation scheme between a transferor and transferee within the same group.

    Rationale

    • Aims to reduce costs, achieve synergies, and strengthen growth via consolidation.

    Key Terms & Structure

    • Nature: amalgamation; Appointed Date: 01-01-2025; effective date on sanction filing.
    • Related-party/arm's-length status not explicitly stated.
    • NCLT sanction granted; effective date to be communicated after filing with ROC.
    • Share exchange: 10 transferee shares for every 36 transferor shares.
    • Assets and liabilities of the transferor transfer to the transferee.
    • Accounting: pooling of interest; assets/liabilities recorded at book values.
    • Capital impact: excess share capital moved to capital reserve.
    • Record date to be fixed mutually after sanction.
    • No auto-modification without tribunal approval.
    • Dissolution: Transferor dissolved on scheme effectiveness.

    Financial Impact

    • Shareholders of transferor receive 10 equity shares of transferee per 36 transferor shares.
    • All assets and liabilities vest in transferee at book values.
    • Difference between assets' capital value and transferor capital moved to capital reserve.
    • Inter-se investments as on appointed date will be cancelled.
    • Tax liabilities reserved for recovery under applicable law.
    • Post-merger accounting to follow pooling-of-interest method under Ind AS 103.

    Stakeholders

    • Employees of transferor become employees of transferee with continuous service.
    • Employee protections and no retrenchment for staff dated to Appointed Date.
    • Creditors' debts and obligations transfer to transferee.
    • Shareholders of transferor will hold shares in transferee per ratio.
    • Listing status of transferee unaffected by scheme.
    • Operations may consolidate; cost efficiencies expected.

    Status & Next Steps

    • NCLT sanctioned the scheme on 02 July 2026.
    • Effective date upon filing the sanction order with ROC.
    • Record date to be fixed post-sanction; filings and MOA/AOA adjustments anticipated.
    • Petition disposed; scheme implementation to follow regulatory filings.
    View source

  9. Steel Exchange India Ltd

    SEIL reports ₹102 crore debt reduction; ~30% of long-term debt repaid since December 2025

    Press Release / Media Release

    Debt reduction progress

    • Total debt reduction reaches ₹102 crore since December 2025.
    • Additional ₹16 crore prepayment toward term loan facilities.
    • Prior debt repayments included ₹43.19 crore NCDs and ₹86 crore other term loans.

    Debt freedom and cost implications

    • ~30% of total long-term debt discharged since Dec 2025.
    • Lower finance costs expected, improving margins and earnings quality.

    FY26 financials

    • FY26 total income ₹1,067 crore, EBITDA ₹138.03 crore, net profit ₹27 crore.

    Outlook and strategy

    • Aim to become debt-free in the near term.
    • Strategy relies on cash generation and equity inflows.
    View source

  10. Clean Max Enviro Energy Solutions Ltd

    CleanMax reports record quarterly commissioning of over 500 MW; portfolio reaches 4.2 GW

    Press Release / Media Release

    Key Highlights

    • Commissioned ~530 MW in Q1 FY27, highest quarterly.
    • Operational portfolio now ~4.2 GW; RE Power Sales ~3.5 GW, RE Services ~0.7 GW.
    • Largest additions in Gujarat (~170 MW), Karnataka (~160 MW), Maharashtra (~110 MW).
    • Commissioning across 11 sites in five states.
    • RE Power Sales added ~403 MW; RE Services added ~126 MWp.
    • FY2025-26 contracted portfolio at 5.7 GW; 74% from existing customers.
    • CARE Ratings upgraded to AA-/Stable in May 2026.
    • 588 customers served; 42% of RE Power Sales from Data Centers & AI infra.
    • New wins include Meta, Apple, STT GDC India, Iron Mountain, CEAT, GACL.
    View source